RECEIVED **CENTRAL FAX CENTER**

STITES & HARBISON PLLC

ATTORNEYS

AUG 2 2 2005

400 West Market Street Suite 1800 Louisville, KY 40202-3352 [502] 587-3400 [502] 587-6391 FAX www.stites.com

FAX TRANSMISSION

Notice of Confidentiality

This Communication is Directed Solely To The Addressee And May Contain Confidential or Legally Privileged Information

If You Are Not The Addressee Indicated Below:

Do not read the following pages

Do not retain, copy, distribute or disseminate the following pages

Please call the sender immediately (collect if necessary) and return the original and all copies to the above addressee (we will reimburse postage)

NEITHER THE TRANSMISSION OF THE ATTACHED PAGES, NOR ANY ERROR IN TRANSMISSION OR MISDELIVERY SHALL CONSTITUTE WAIVER OF ANY APPLICABLE LEGAL PRIVILEGE

DATE: August 22, 2005 TO:

NAME:	FAX NO.:	PHONE NO.:
Examiner – Steam USPTO – Group Art Unit 1634	(571)-273-8300	
OSPIO - GIOUP AIL OIN 1437	703-872-9306	<u> </u>

NUMBER OF PAGES (INCLUDING COVER PAGE):

IF ALL PAGES ARE NOT RECEIVED, ARE ILLEGIBLE OR ARE RECEIVED IN ERROR. PLEASE CALL [502] 681-0665 AS SOON AS POSSIBLE

FROM:

Mandy V. Wilson

C/M CODE:

UNLV 01010 (UN024/0UN22)

TRANSMITTED BY: mvw

MESSAGE:

PLEASE SEE ATTA

Application No. 09/820,531 Reply to Office Action of June 20, 2005

AUG 2 2 2005

IN THE U.S. PATENT AND TRADEMARK OFFICE

U.S. Patent Application S.N. 09/820,531

MICROARRAYS TO SCREEN REGULATORY GENES

inventor(s):

March 29, 2001

Group Art Unit: 1634

B. Sisson

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile to Examiner Bradley L. Sisson, Group Art Unit 1634 of the United States Patent and Trademark Office, Alexandria, VA 22313 to controlized facsimile number (571)-273-8300, on Monday, August 22, 2005.

Name Manager Wickson
Signature

REPLY PURSUANT TO 37 CFR 8 1.111

Commissioner of Patents Alexandria, VA 22313-1450

This Reply is being filed in response to the Office Action dated June 20, 2005. It is believed that no fee is due with this Amendment; however, if a fee is required, the Commissioner is hereby authorized to charge or credit Deposit Account No. 502752.

· Insues under 35 U.S.C. 88 101 and 112

In the Office Action dated June 20, 2005, the Examiner rejected the pending claims under 25 U.S.C. §§ 101 and 112 using largely the same arguments supplied in the Office Action dated November 24, 2004. In making these rejections, the Examiner construed the claims "as encompassing one suspending time...air, light, any temperature, pressure, gravity, etc." and then argued that the claims-so-construed were not adequately described in the specification, were not enabled, and lacked utility.

In the response to the Office Action dated November 24, 2004, Applicant did not argue "that the interpretation of "exogenous agent" was overly broad," as suggested in the Office Action dated June 20, 2005. Indeed, Applicant agrees with the Examiner in that "the art recognizes a tremendously broad array of exogenous agents as having, or potentially having an effect on genes of interest." In the response to the Office Action dated November 24, 2004, the Applicant submitted an argument that a reading of the language of the claims, given their ordinary meaning, would not involve the suspension of time or the blocking of any and all exogenous agents.

The meaning of the following claim language is at issue: "screening a sample microarray comprising genes ... exposed to the disease, age or exogenous agent ...; and comparing the

The Examiner argues that this language encompasses suspi

onstrued, there would be no basis for any rejection contained in the Office Action. Applicant anibrodeus sa *sloug-stop oldinacemi* sangemeers fox sace agougsus scient act test attenden

Contemporaneously filed with this Ar nondment is a Declaration under 37 CFR 1.132 by contention that one of ordinary skill in the art would not understand the claims to encompass

It is respectfully submitted that one of ordinary skill in the art w is never expected to be removed from the basic effects of the environment when submitted which the test surple is subjected. The claim language reasonably convoys to one of ordinary to which the genes of the sample microarray are exp

Recume the claims in not encompant the whilly in ampend from nor the oblity to creat ditions to eliminate exposure to any and all exogenous agents, the rejections pursuant to 35 present invention is useful because it identifies clipracteristics, in administrative of interest by mumbragas branggonuts campaga inigh g puniformily defined information for multiple samples to one another. For example, oteristics identified through the method of the present invention for samples of interest may include a historialism imiter of grinn end/or forest of a particular gene or a group of genes,

Application No. 09/820,531 Reply to Office Action of June 20, 2005

relative to the other samples. Changes in gene expression have been found to correlate with diseases or disorders and identification of such changes allow for diagnosis and assessment of potential treatments. See e.g., US Application Publication 2002/0009736, Paragraphs [0061] [0073].

In light of the foregoing remarks and the Declaration submitted herewith, Applicant respectfully requests allowance of all claims now pending in this Application.

Respectfully submitted,

Mandy V. Wilson, Reg. No. 53,781

STITES & HARBISON, PLLC

400 W. Market Street

Louisville, Kentucky 40202-3352

Phone (502) 587-3400

Facsimile (502) 587-6391